The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms

References

• Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.
   PubMed Web of Science ®Google Scholar
• El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol. 2015;21(25):7621–7636.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gilja OH, Hatlebakk JG. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Mol Med Rep. 2019;20:787–794.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Hausken T. Diet in irritable bowel syndrome (IBS): interaction with gut microbiota and gut hormones. Nutrients. 2019;11(8):1824.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hausken T, Hatlebakk JG. Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(11):e14157.
   PubMed Web of Science ®Google Scholar
• Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2019;114(7):1043–1050.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Kristoffersen AB, Valeur J, et al. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2022;34(1):e14200.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021;160(1):145–157.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859–867.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, European FMT Working Group, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569–580.
   PubMed Web of Science ®Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Tther. 1997;11(2):395–402.
   PubMed Web of Science ®Google Scholar
• Hendriks C, Drent M, Elfferich M, et al. The fatigue assessment scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. 2018;24(5):495–503.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterology. 2000;95(4):999–1007.
   PubMed Web of Science ®Google Scholar
• Wong RK, Drossman DA. Quality of life measures in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010;4(3):277–284.
   PubMed Web of Science ®Google Scholar
• Arslan G, Lind R, Olafsson S, et al. Quality of life in patients with subjective food hypersensitivity: applicability of the 10-item short form of the Nepean dyspepsia index. Dig Dis Sci. 2004;49(4):680–687.
   PubMed Web of Science ®Google Scholar
• Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71–83.
   PubMed Web of Science ®Google Scholar
• Enck P, Mazurak N. Dysbiosis in functional bowel disorders. Ann Nutr Metab. 2018;72(4):296–306.
   PubMed Web of Science ®Google Scholar
• Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17–24.
   PubMed Web of Science ®Google Scholar
• Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107–2115.
   PubMed Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019;4(9):675–685.
   PubMed Web of Science ®Google Scholar
• Holster S, Lindqvist CM, Repsilber D, et al. The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study. Clin Transl Gastroenterol. 2019;10(4):e00034.
   PubMed Web of Science ®Google Scholar
• Lahtinen P, Jalanka J, Hartikainen A, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020;51(12):1321–1331.
   PubMed Web of Science ®Google Scholar
• DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043–2050.
   PubMed Web of Science ®Google Scholar
• Blaser MJ. Fecal microbiota transplantation for dysbiosis - predictable risks. N Engl J Med. 2019;381(21):2064–2066.
   PubMed Web of Science ®Google Scholar
• Perler BK, Chen B, Phelps E, et al. Long-term efficacy and safety of fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection. J Clin Gastroenterol. 2020;54(8):701–706.
   PubMed Web of Science ®Google Scholar
• Ooijevaar RE, van Nood E, Goorhuis A, et al. Ten-year follow-up of patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection from a randomized controlled trial and review of the literature. Microorganisms. 2021;9(3):548.
   PubMed Web of Science ®Google Scholar
• Merrick B, Allen L, Masirah MZN, et al. Regulation, risk and safety of faecal microbiota transplant. Infect Prev Pract. 2020;2(3):100069.
   PubMedGoogle Scholar
• Cold F, Svensson CK, Petersen AM, et al. Long-term safety following faecal microbiota transplantation as a treatment for recurrent Clostridioides difficile infection compared with patients treated with a fixed bacterial mixture: results from a retrospective cohort study. Cells. 2022;11(3):435.
   PubMed Web of Science ®Google Scholar
• Barbara G, Ianiro G. Faecal microbial transplantation in IBS: ready for prime time? Gut. 2020;69(5):795–796.
   PubMed Web of Science ®Google Scholar
• Camilleri M. FMT in IBS: a call for caution. Gut. 2021;70(2):431.
   PubMed Web of Science ®Google Scholar
• El-Salhy M. FMT in IBS: how cautious should we be? Gut. 2021;70(3):626.1–628.
   Web of Science ®Google Scholar
• Karcher N, Pasolli E, Asnicar F, et al. Analysis of 1321 Eubacterium rectale genomes from metagenomes uncovers complex phylogeographic population structure and subspecies functional adaptations. Genome Biol. 2020;21(1):138.
   PubMed Web of Science ®Google Scholar
• Zou Y, Liang N, Zhang X, et al. Functional differentiation related to decomposing complex carbohydrates of intestinal microbes between two wild zokor species based on 16SrRNA sequences. BMC Vet Res. 2021;17(1):216.
   PubMed Web of Science ®Google Scholar
• Zhang J, Song L, Wang Y, et al. Beneficial effect of butyrate-producing lachnospiraceae on stress-induced visceral hypersensitivity in rats. J Gastroenterol Hepatol. 2019;34(8):1368–1376.
   PubMed Web of Science ®Google Scholar
• Long X, Li M, Li LX, et al. Butyrate promotes visceral hypersensitivity in an IBS-like model via enteric glial cell-derived nerve growth factor. Neurogastroenterol Motil. 2018;30(4):e13227.
   PubMed Web of Science ®Google Scholar
• Banasiewicz T, Krokowicz L, Stojcev Z, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013;15(2):204–209.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Hatlebakk JG, Hausken T. Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides. 2020;79:101973.
   PubMed Web of Science ®Google Scholar
• Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–119.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Valeur J, Hausken T, et al. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(2):e13983.
   PubMed Web of Science ®Google Scholar
• Winston J, Shenoy M, Medley D, et al. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007;132(2):615–627.
   PubMed Web of Science ®Google Scholar